Creating, facilitating and promoting sustainable Health Technology Assessment (HTA) cooperation in Europe
The final report is now available for the Relative Effectiveness Assessment OTCA26 “Surgical procedures for treatment of obesity”. The aim of this multi-technology HTA was
PTJA16 – Venetoclax in combination with an hypomethylating agent for treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy – final assessment now available
This is the pharmaceutical Joint Assessment PTJA16 – Venetoclax with a hypomethylating agent fort he treatment of adult patients with newly diagnosed acute myeloid leukaemia
We are pleased to publish the minutes for the EUnetHTA-EMA Bilateral meeting held online on 28 April, 2021. This meeting concluded the EMA/EUnetHTA work plan
PTRCR20 – Bamlanivimab for the treatment of COVID-19 Rapid Collaborative Review- Final Rapid Collaborative Review now available.
This is the fourth pharmaceutical Rapid Collaborative Review (PTRCR20) published by EUnetHTA. In March 2021, after an Article 5(3) review the European Medicines Agency (EMA) endorsed